Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com
MISSISSAUGA, Ontario, May 8, 2017 /CNW/ -- Profound Medical Corp. (OTCQX: PRFMF; TSX-V:PRN), based in Ontario, an emerging medical device company focused on prostate care, today announced that Arun Menawat, CEO, will present live at VirtualInvestorConferences.com on May 11, 2017.
DATE: Thursday, May 11, 2017
TIME: 12:30 PM ET
This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the association's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.
It is recommended that investors pre-register and run the online system check to save time and receive event updates.
Learn more about the event at www.VirtualInvestorConferences.com.
Recent Company Highlights
- Profound Medical Corp. announced its common shares are available for trading on the OTCQX® Best Mark starting March 13, 2017
- Profound Medical Corp. announced on April 18th it secured Depository Trust Company (DTC) eligibility for its shared traded on the OTCQX market.
About Profound Medical Corp.
The Profound Medical team is committed to the effort to achieve a new therapeutic standard in prostate cancer. For the millions of men currently living with prostate cancer, and the thousands more who are diagnosed with it every year, current treatment options often mean having to make difficult choices based on potential side effects that can significantly impact quality of life. Our mission is to profoundly change the standard of care by creating a tomorrow where clinicians can confidently ablate cancerous prostate tissue with precision, while actively protecting critical anatomy from potential side effects; a tomorrow where patients have access to a safe, fast and effective treatment option, so they can quickly return to their daily lives.
Established in 2008, Profound Medical is commercializing a novel technology, TULSA-PRO® system, which combines real-time Magnetic Resonance Imaging with transurethral, robotically-driven therapeutic ultrasound and closed-loop thermal feedback control that is designed to provide precise ablation of the prostate while simultaneously protecting critical surrounding anatomy from potential side effects. TULSA-PRO® system is CE Marked and Profound is sponsoring a multicenter, prospective FDA-registered clinical trial, TACT Pivotal Clinical Trial, which is designed to further demonstrate the safety and effectiveness of this innovative technology.
Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PRNewswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.
Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.
SOURCE Profound Medical Corp.
For further information: Profound Medical Corp.: Stephen Kilmer, Investor Relations, 647.872.4849, [email protected]; Rashed Dewan, Vice President, Finance, 647.476.1350; VirtualInvestorConferences.com: Bradley H. Smith, Director of Marketing, IR and Compliance Services, PR Newswire, +1.201.947.7157, [email protected]